Evidence map›Paper›PMID 35574031›Full record

ArticleFrontiers in endocrinology2022

Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.

Yi Luo, Yi-Chen Yang, Cen-Kai Shen, Ben Ma, Wei-Bo Xu, Qi-Feng Wang, Yan Zhang, Tian Liao, Wen-Jun Wei, Yu Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yi LuoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yi-Chen YangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cen-Kai ShenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ben MaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wei-Bo XuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Qi-Feng WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yan ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tian LiaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wen-Jun WeiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yu WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with advanced thyroid carcinoma (TC), such as anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), and locally advanced papillary thyroid carcinoma (PTC), have poor prognoses and require novel treatments. Immune checkpoint (ICP) inhibitors have demonstrated encouraging and good results; nevertheless, their effect in advanced TCs remains largely unclear. Thus, we demonstrated ICP profiles and investigated their potential clinical significance. Methods: A total of 234 TC patients were involved, with 22 ATCs, 44 PDTCs, and 168 PTCs, including 58 advanced PTCs. Immunohistochemistry was performed to evaluate nine ICPs [programmed cell death ligand 1 (PDL1), Programmed cell death 1 (PD1), cytotoxic T lymphocyte-associated protein 4 (CTLA4), B and T lymphocyte attenuator (BTLA), T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT), lymphocyte activation gene 3 (LAG3), V-domain immunoglobulin suppressor of T-cell activation (VISTA), B7 homolog 3 (B7-H3), and T-cell immunoglobulin and mucin domain- 3 protein (TIM3)] expression Results: ATC had the highest positive rate of ICPs among the three pathological types, as well as relatively high ICP co-expression. ATC with high expression of PDL1 positivity had a poor prognosis. Shorter survival was associated with VISTA, B7H3, TIM3, and TIGIT expression in PDTC. The greater the co-expression of these four ICPs, the poorer the prognosis in PDTC patients. VISTA and B7H3 were the two most commonly expressed ICPs in advanced PTC, both of which were linked to a poor prognosis. Conclusions: PDL1 is linked to the overall survival (OS) of ATC. A subset of PDTC is likely immunogenic with poor prognosis and co-expression of VISTA, B7H3, TIM3, and TIGIT. Furthermore, VISTA and B7H3 are prognostic biomarkers in advanced PTC. Single or combined blockade targeting these ICPs might be effective for advanced TCs in the future.

Indexed as

AdenocarcinomaThyroid Carcinoma, AnaplasticThyroid NeoplasmsHepatitis A Virus Cellular Receptor 2HumansImmune Checkpoint ProteinsImmunoglobulinsPrognosisReceptors, ImmunologicThyroid Cancer, PapillaryHepatitis A Virus Cellular Receptor 2Immune Checkpoint ProteinsImmunoglobulinsReceptors, Immunologicanaplastic thyroid carcinomaimmune checkpointimmunotherapylocally advanced papillary thyroid carcinomapoorly differentiated thyroid carcinoma

Identifiers

PMID35574031
PMCPMC9094437
OpenAlexW4224923186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.